Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCC.OQ)

CYCC.OQ on NASDAQ Stock Exchange Capital Market

1.68USD
18 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.68
Open
$1.66
Day's High
$1.68
Day's Low
$1.64
Volume
24,266
Avg. Vol
44,980
52-wk High
$10.90
52-wk Low
$1.56

CYCC.OQ

Chart for CYCC.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.36
Market Cap(Mil.): $19.15
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

  CYCC.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -2.42 -- --
ROI: -75.99 2.83 14.89
ROE: -78.45 5.09 16.13

BRIEF-Cyclacel Pharmaceuticals Q2 loss per share $0.50

* Cyclacel Pharmaceuticals reports second quarter 2017 financial results

Aug 09 2017

BRIEF-Intra-Cellular Therapies reports Q2 loss per share $0.41

* Intra-Cellular Therapies reports second quarter 2017 financial results and provides corporate update

Aug 09 2017

BRIEF-Cyclacel announces selection of recommended phase 2 dose for CYC065

* Cyclacel announces selection of recommended phase 2 dose for CYC065 and evidence of durable target engagement and MCL-1 biomarker suppression Source text for Eikon: Further company coverage:

Aug 07 2017

BRIEF-Cyclacel announces pricing of $13.2 mln underwritten public offering

* Cyclacel announces pricing of $13.2 million underwritten public offering

Jul 19 2017

BRIEF-Cyclacel Pharmaceuticals says approved extension of employment agreements with CEO and CFO

* Cyclacel pharmaceuticals - compensation and organization development committee approved extension of employment agreements with ceo spiro rombotis, cfo paul mcbarron

Jun 27 2017

BRIEF-Cyclacel Pharma files for potential offering of up to $15 mln

* Cyclacel pharmaceuticals inc- files for potential offering of up to $15 million - sec filing Source text for Eikon: Further company coverage:

May 26 2017

BRIEF-Cyclacel Pharmaceuticals Q1 loss per share $0.38

* Cyclacel pharmaceuticals reports first quarter 2017 financial results

May 11 2017

BRIEF-Intra-Cellular therapies reports Q1 loss per share $0.62

* Intra-Cellular therapies reports first quarter 2017 financial results and provides corporate update

May 10 2017

BRIEF-Intra-Cellular Therapies provides corporate update on schizophrenia program

* Intra-Cellular Therapies provides corporate update on schizophrenia program

May 01 2017

BRIEF-Cyclacel presents identification of sensitive target indications, synergistic drug combinations for novel PLK1 inhibitor CYC140

* Cyclacel presents identification of sensitive target indications and synergistic drug combinations for novel plk1 inhibitor cyc140

Apr 04 2017

Competitors

Earnings vs. Estimates